查詢結果分析
相關文獻
- Cardiac Resynchronization Therapy for Drug-Refractory Heart Failure: A Single-Center Experience
- 心臟衰竭治療的新契機--心臟再同步化治療
- 由充血性心臟衰竭的治療進展談起--中醫研究之困境
- 醫師處方評估及病患用藥指導: 乙種維生素缺乏引起之心臟病變
- "HeartMate"心伴左心室輔助幫浦在重度心臟衰竭病人之應用
- Dopamine and Dobutamine Have Different Effects on Heart Rate Variability in Patients with Congestive Heart Failure
- Treatment of Heart Failure
- 病例介紹與用藥檢討(17)--鬱血性心臟衰竭(Congestive Heart Failure)
- Pacing Therapy in Congestive Heart Failure
- Ten-Year Study of Infective Endocarditis: Clinical Features at Different Locations
頁籤選單縮合
題 名 | Cardiac Resynchronization Therapy for Drug-Refractory Heart Failure: A Single-Center Experience=藥物難以治療的心臟衰竭之心臟再同步化治療,一個醫學中心之經驗 |
---|---|
作 者 | 曾聖雄; 林文裕; 鄭正忠; 劉俊廷; 汪文斌; 蔡國勝; 曾炳憲; 鄭書孟; 林維祥; | 書刊名 | Journal of Medical Sciences |
卷 期 | 31:3 2011.06[民100.06] |
頁 次 | 頁103-108 |
分類號 | 415.319 |
關鍵詞 | 心臟衰竭; 心臟再同步化治療; Cardiac-resynchronization therapy; Heart failure; Left ventricular function; |
語 文 | 英文(English) |
英文摘要 | Background: Heart failure (HF) is associated with high mortality and morbidity rates even after pharmacological treatment. This retrospective study aimed at analyzing the clinical benefits and patient outcomes after cardiac resynchronization therapy (CRT). Methods: We enrolled 12 patients with New York Heart Association (NYHA) functional class III or IV HF, a left ventricular ejection fraction (LVEF) of ≦35%, and an intrinsic QRS duration of ≧120 ms. These patients were refractory to pharmacological treatment and underwent CRT-device implantation. Results: After a mean follow-up of 6 months after device implantation, the mean values of NYHA functional class has decreased and the values of LV remodeling parameters, namely the LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), and LVEF, had improved. The treatment resulted in a 58% reduction in the frequency of HF-related hospitalization, and cardiac-cause mortality was 8% for the entire study group; the corresponding values were 42.8% and 14.3% for patients with ischemic HF and 80% and 0% for those with non-ischemic HF. Both patients with ischemic and non-ischemic HF showed improvement in all the LV remodeling parameters. None of the patients developed any immediate complication of device implantation but 1 patient developed left subclavian vein thrombosis 2 months after device implantation and was treated successfully with anti-coagulant therapy. Conclusions: This small-scale, retrospective study of a drug refractory HF cohort revealed that CRT improves the quality of life, LVEF, LVEDD, and LVESD, and reduces cardiac-cause mortality and the frequency of HF related hospitalization both in ischemic and non-ischemic HF patients. |
本系統中英文摘要資訊取自各篇刊載內容。